戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 evention (CDC) Foundation (with support from Amgen).
2 search UK, CDC Foundation (with support from Amgen).
3  Canadian Cancer Society Research Institute, Amgen.
4 Cancer Society, Celgene (a BMS company), and AMGEN.
5 es of Health, National Cancer Institute, and Amgen.
6  Viela Bio/Horizon Therapeutics, now part of Amgen.
7 search UK, Celgene, Merck Sharp & Dohme, and Amgen.
8                                              Amgen and Celgene (Bristol Myers Squibb).
9 S National Institutes of Health, and AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Genentech, and
10 ncil, Novartis Pharmacy B V Oncology Europe, Amgen, BMS/Celgene International, Janssen Pharmaceutica,
11                                Immunomedics, Amgen, Canceropole Grand Ouest, the GOELAMS/LYSA group a
12 nd Medical Research Council in Australia and Amgen Competitive Grant Program 2019.
13 combination of substructure searching of the Amgen compound collection based on a minimal binding pha
14                                              Amgen, Eli Lilly, and National Institutes of Health.
15                                              Amgen, Eli Lilly, National Center for Research Resources
16 d oHSV biotherapeutics: Imlygic, marketed by Amgen for the treatment of advanced melanoma in the Unit
17                 Cancer Research UK, Celgene, Amgen, Merck, and Myeloma UK.
18                 Cancer Research UK, Celgene, Amgen, Merck, Myeloma UK.
19                          Cancer Research UK, Amgen, Pfizer, and Roche.
20 atients, study personnel, investigators, and Amgen study staff were masked to treatment assignments w
21 Pharmaceuticals and Onyx Pharmaceuticals (an Amgen subsidiary).
22               Onyx Pharmaceuticals, Inc., an Amgen subsidiary.
23 analyses not sponsored by either Novartis or Amgen, the makers of ZA and denosumab, respectively.
24                                              Amgen, UK National Institute for Health Research Biomedi